HRP20240924T1 - Anti - sirpalpha antitijela - Google Patents
Anti - sirpalpha antitijela Download PDFInfo
- Publication number
- HRP20240924T1 HRP20240924T1 HRP20240924TT HRP20240924T HRP20240924T1 HR P20240924 T1 HRP20240924 T1 HR P20240924T1 HR P20240924T T HRP20240924T T HR P20240924TT HR P20240924 T HRP20240924 T HR P20240924T HR P20240924 T1 HRP20240924 T1 HR P20240924T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino acid
- acid sequence
- sirpα antibody
- sequence seq
- antibody
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Anti-SIRPα protutijelo ili njegov fragment koji veže antigen, koji sadrži varijabilnu regiju (VR) teškog lanca (HC) i lakog lanca (LC) koja određuje komplementarnost (CDR) CDR1, CDR2 i CDR3, pri čemu:
a. HC VR CDR1 sastoji se od aminokiselinske sekvence HGIS,
b. HC VR CDR2 sastoji se od aminokiselinske sekvence TIGTGVITYFASWAKG,
c. HC VR CDR3 sastoji se od aminokiselinske sekvence GSAWNDPFDP,
d. LC VR CDR1 sastoji se od aminokiselinske sekvence QASQSVYGNNDLA,
e. LC VR CDR2 sastoji se od aminokiselinske sekvence LASTLAT, tj
f. LC VR CDR3 sastoji se od aminokiselinske sekvence LGGGDDEADNV
gdje su CDR-ovi označeni prema Kabatovoj numeraciji.
2. Anti-SIRPα antitijelo ili njegov antigen-vezujući fragment sukladno zahtjevu 1, naznačeno time da je kimerno, humanizirano ili humano.
3. Anti-SIRPα antitijelo ili njegov antigen-vezujući fragment sukladno zahtjevu 2, naznačeno time da je humanizirano.
4. Humanizirano anti-SIRPα protutijelo ili njegov fragment koji veže antigen sukladno zahtjevu 3, naznačeno time što sadrži
a. HC VR aminokiselinska sekvenca SEQ ID NO:35 i LC VR aminokiselinska sekvenca SEQ ID NO:36;
b. HC VR aminokiselinska sekvenca SEQ ID NO:35 i LC VR aminokiselinska sekvenca SEQ ID NO:37;
c. HC VR aminokiselinska sekvenca SEQ ID NO:13 i LC VR aminokiselinska sekvenca SEQ ID NO:38; ili
d. HC VR aminokiselinska sekvenca SEQ ID NO:13 i LC VR aminokiselinska sekvenca SEQ ID NO:37.
5. Anti-SIRPα antitijelo sukladno bilo kojem od zahtjeva 1 do 4, koje sadrži modificiranu Fc regiju koja pokazuje smanjeno vezanje na ljudski Fca ili Fcy receptor u usporedbi s istim anti-SIRPα antitijelom koja sadrži Fc regiju divljeg tipa.
6. Anti-SIRPα protutijelo sukladno zahtjevu 5, koje sadrži modificiranu ljudsku IgGi Fc regiju koja sadrži aminokiselinske supstitucije na jednom ili više položaja odabranih iz skupine koju čine L234, L235, G237, D265, D270, N297, A327, P328 , i P329 prema EU numeraciji.
7. Anti-SIRPα protutijelo sukladno zahtjevu 6, naznačeno time da sadrži aminokiselinske supstitucije L234A i L235A; L234E i L235A; L234A, L235A i P329A; ili L234A, L235A i P329G.
8. Anti-SIRPα protutijelo sukladno zahtjevu 7, naznačeno time da sadrži aminokiselinske supstitucije L234A i L235A; ili L234E i L235A.
9. Farmaceutski pripravak, naznačen time, da sadrži anti-SIRPα antitijelo sukladno bilo kojem od zahtjeva 1 do 8 i jedan ili više farmaceutski prihvatljivih ekscipijenata.
10. Anti-SIRPα antitijelo sukladno bilo kojem od zahtjeva 1 do 8 ili farmaceutski pripravak sukladno zahtjevu 9 za upotrebu kao lijek.
11. Anti-SIRPα antitijelo sukladno bilo kojem od zahtjeva 1 do 8 ili farmaceutski pripravak sukladno zahtjevu 9 za upotrebu u liječenju humanih solidnih tumora ili hematoloških zloćudnih bolesti.
12. Kombinacija anti-SIRPα protutijela sukladno bilo kojem od zahtjeva 1 do 8 ili farmaceutskog pripravka sukladno zahtjevu 9 s jednim ili više drugih terapeutika protiv raka za upotrebu u liječenju humanih solidnih tumora ili hematoloških zloćudnih bolesti.
13. Kombinacija za upotrebu sukladno zahtjevu 12, naznačena time što su jedan ili više drugih terapeutika protiv raka ciljani terapeutici ili imunoterapijski agensi.
14. Kombinacija za upotrebu sukladno zahtjevu 13, naznačena time što je ciljani terapeutik terapeutsko protutijelo ili konjugat protutijelo-lijek.
15. Kombinacija za upotrebu sukladno zahtjevu 14, naznačena time što je terapijsko protutijelo terapijsko protutijelo protiv cilja vezanog na membranu na površini tumorskih stanica koje sadrže ljudsku Fc regiju koja se veže na aktiviranje Fc receptora prisutnih na ljudskim imunološkim efektorskim stanicama .
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171285 | 2017-05-16 | ||
| EP18729328.7A EP3625259B1 (en) | 2017-05-16 | 2018-05-15 | Anti-sirpalpha antibodies |
| PCT/EP2018/062473 WO2018210793A2 (en) | 2017-05-16 | 2018-05-15 | ANTI-SIRPα ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240924T1 true HRP20240924T1 (hr) | 2024-10-11 |
Family
ID=58714966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240924TT HRP20240924T1 (hr) | 2017-05-16 | 2018-05-15 | Anti - sirpalpha antitijela |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11274159B2 (hr) |
| EP (2) | EP3625259B1 (hr) |
| JP (1) | JP7171617B2 (hr) |
| KR (1) | KR102714600B1 (hr) |
| CN (2) | CN110799536B (hr) |
| AR (1) | AR111630A1 (hr) |
| AU (1) | AU2018268304B2 (hr) |
| BR (1) | BR112019023754A2 (hr) |
| CA (1) | CA3063622A1 (hr) |
| CL (1) | CL2019003266A1 (hr) |
| DK (1) | DK3625259T3 (hr) |
| ES (1) | ES2981193T3 (hr) |
| FI (1) | FI3625259T3 (hr) |
| HR (1) | HRP20240924T1 (hr) |
| HU (1) | HUE067040T2 (hr) |
| LT (1) | LT3625259T (hr) |
| MX (1) | MX2019013749A (hr) |
| MY (1) | MY199247A (hr) |
| PL (1) | PL3625259T3 (hr) |
| PT (1) | PT3625259T (hr) |
| RU (1) | RU2771174C2 (hr) |
| TW (1) | TWI710574B (hr) |
| WO (2) | WO2018210795A1 (hr) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA126658C2 (uk) | 2016-04-14 | 2023-01-11 | Осе Іммьюнотерапьютікс | НОВІ АНТИТІЛА ДО SIRPa ТА ВАРІАНТИ ЇХ ТЕРАПЕВТИЧНОГО ЗАСТОСУВАННЯ |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| WO2018107058A1 (en) | 2016-12-09 | 2018-06-14 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
| WO2018190719A2 (en) * | 2017-04-13 | 2018-10-18 | Aduro Biotech Holdings, Europe B.V. | Anti-sirp alpha antibodies |
| CN118344481A (zh) | 2018-03-21 | 2024-07-16 | Alx肿瘤生物技术公司 | 针对信号调控蛋白α的抗体和使用方法 |
| CN112218893B (zh) | 2018-05-25 | 2025-01-14 | 艾利妥 | 抗-sirpa抗体及其使用方法 |
| WO2020006374A2 (en) * | 2018-06-29 | 2020-01-02 | Alector Llc | Anti-sirp-beta1 antibodies and methods of use thereof |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| KR20210086619A (ko) | 2018-09-27 | 2021-07-08 | 셀진 코포레이션 | SIRPα 결합 단백질 및 이의 사용 방법 |
| MY204673A (en) * | 2018-11-15 | 2024-09-09 | Byondis Bv | Humanized anti-sirp antibodies |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| PH12021553256A1 (en) | 2019-06-25 | 2022-08-08 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
| EP4052040A1 (en) | 2019-10-31 | 2022-09-07 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| CN116769031A (zh) * | 2019-12-24 | 2023-09-19 | 礼新医药科技(上海)有限公司 | 抗SIRPα单克隆抗体及其用途 |
| CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| US12343377B2 (en) | 2020-06-01 | 2025-07-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
| EP4253416A4 (en) * | 2020-11-30 | 2024-11-13 | Qure Biotechnology (Shanghai) Co., Ltd. | ANTI-SIRPALPHA ANTIBODY OR ASSOCIATED ANTIGEN-BINDING FRAGMENT, AND USE THEREOF |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CN112574310B (zh) * | 2020-12-11 | 2023-05-05 | 浙江博锐生物制药有限公司 | 抗SIRPα抗体及其用途 |
| CN112979782B (zh) * | 2021-03-08 | 2023-07-18 | 深圳市乐土生物医药有限公司 | 一种多肽及其用途 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| MX2023014389A (es) * | 2021-06-04 | 2024-03-04 | Boehringer Ingelheim Int | Anticuerpos anti-sirp-alfa. |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| WO2023020459A1 (zh) * | 2021-08-17 | 2023-02-23 | 杭州九源基因工程有限公司 | 靶向SIRPα的单克隆抗体及其用途 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CR20240173A (es) | 2021-10-29 | 2024-06-20 | Gilead Sciences Inc | Compuestos de cd73 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| CN120202222A (zh) | 2022-11-16 | 2025-06-24 | 勃林格殷格翰国际有限公司 | 抗SIRPa抗体的疗效预测性生物标志物 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220895A1 (en) * | 2023-04-20 | 2024-10-24 | Twist Bioscience Corporation | Antibodies and variant nucleic acid libraries for sirp-alpha |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN116715774B (zh) * | 2023-05-12 | 2023-11-24 | 武汉爱博泰克生物科技有限公司 | 针对人axl的兔单克隆抗体及其制备方法和应用 |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118344476B (zh) * | 2024-05-16 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用 |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU1701001A (en) * | 1999-11-30 | 2001-06-12 | Eberhard-Karls-Universitat Tubingen Universitatsklinikum | Antibodies against signal regulator proteins |
| EP2471813B1 (en) * | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| ES2566538T3 (es) | 2011-01-19 | 2016-04-13 | Cantargia Ab | Anticuerpos anti-IL1RAP y su uso para el tratamiento de tumores sólidos |
| WO2013056352A1 (en) * | 2011-10-19 | 2013-04-25 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| WO2013150043A1 (en) * | 2012-04-05 | 2013-10-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies against human tweak and human il17 and uses thereof |
| CA2874721A1 (en) | 2012-05-30 | 2013-12-05 | Tomoyuki Igawa | Target tissue-specific antigen-binding molecule |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP3116544A4 (en) * | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| CA2994935A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| US20180312600A1 (en) * | 2015-10-21 | 2018-11-01 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| AU2017248626B2 (en) | 2016-04-14 | 2024-05-09 | Ose Immunotherapeutics | New anti-SIRPa antibodies and their therapeutic applications |
| CN109862910A (zh) | 2016-08-03 | 2019-06-07 | 小利兰·斯坦福大学托管委员会 | 破坏巨噬细胞上的Fc受体接合增强抗SIRPα抗体疗法的功效 |
-
2018
- 2018-05-15 MY MYPI2019006658A patent/MY199247A/en unknown
- 2018-05-15 HR HRP20240924TT patent/HRP20240924T1/hr unknown
- 2018-05-15 ES ES18729328T patent/ES2981193T3/es active Active
- 2018-05-15 AU AU2018268304A patent/AU2018268304B2/en active Active
- 2018-05-15 DK DK18729328.7T patent/DK3625259T3/da active
- 2018-05-15 PL PL18729328.7T patent/PL3625259T3/pl unknown
- 2018-05-15 FI FIEP18729328.7T patent/FI3625259T3/fi active
- 2018-05-15 US US16/614,199 patent/US11274159B2/en active Active
- 2018-05-15 PT PT187293287T patent/PT3625259T/pt unknown
- 2018-05-15 HU HUE18729328A patent/HUE067040T2/hu unknown
- 2018-05-15 LT LTEPPCT/EP2018/062473T patent/LT3625259T/lt unknown
- 2018-05-15 EP EP18729328.7A patent/EP3625259B1/en active Active
- 2018-05-15 CN CN201880032714.7A patent/CN110799536B/zh active Active
- 2018-05-15 WO PCT/EP2018/062477 patent/WO2018210795A1/en active Application Filing
- 2018-05-15 CA CA3063622A patent/CA3063622A1/en active Pending
- 2018-05-15 TW TW107116450A patent/TWI710574B/zh active
- 2018-05-15 KR KR1020197037055A patent/KR102714600B1/ko active Active
- 2018-05-15 JP JP2019563581A patent/JP7171617B2/ja active Active
- 2018-05-15 EP EP24169594.9A patent/EP4400173A3/en active Pending
- 2018-05-15 BR BR112019023754A patent/BR112019023754A2/pt unknown
- 2018-05-15 CN CN202410367469.2A patent/CN118271443A/zh active Pending
- 2018-05-15 WO PCT/EP2018/062473 patent/WO2018210793A2/en unknown
- 2018-05-15 RU RU2019141289A patent/RU2771174C2/ru active
- 2018-05-15 MX MX2019013749A patent/MX2019013749A/es unknown
- 2018-05-16 AR ARP180101300A patent/AR111630A1/es not_active Application Discontinuation
-
2019
- 2019-11-14 CL CL2019003266A patent/CL2019003266A1/es unknown
-
2022
- 2022-02-02 US US17/591,231 patent/US11718681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240924T1 (hr) | Anti - sirpalpha antitijela | |
| JP7551693B2 (ja) | ＮＫｐ４６結合タンパク質の可変領域 | |
| ES2801873T3 (es) | Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos | |
| HRP20201144T1 (hr) | Protutijela anti-cd3 i postupci uporabe | |
| JP2018183173A5 (hr) | ||
| HRP20191584T1 (hr) | Anti-cd79b protutijela i načini uporabe | |
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2018522541A5 (hr) | ||
| JP2019533441A5 (hr) | ||
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| JP2016536020A5 (hr) | ||
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| JP2019501883A5 (hr) | ||
| JP2018519364A5 (hr) | ||
| HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| PE20091474A1 (es) | Anticuerpos monoclonales contra la proteina rgm a y sus usos | |
| RU2013110874A (ru) | Антитела против il-18r1 и их применения | |
| HRP20201493T1 (hr) | Anti-alfa-sinukleinska protutijela i postupci uporabe | |
| JP2016505546A5 (hr) | ||
| JPWO2019129221A5 (hr) | ||
| JP2016503067A5 (hr) | ||
| WO2019195313A1 (en) | Anti-vegf antagonist and pedf agonist constructs and uses thereof | |
| CN115991778A (zh) | 抗pd-l1抗体及其用途 |